Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution
Authors
Keywords
-
Journal
CLINICAL DRUG INVESTIGATION
Volume -, Issue -, Pages -
Publisher
Springer Nature
Online
2019-04-01
DOI
10.1007/s40261-019-00773-w
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adjuvant Tyrosine Kinase Inhibitors (Tki) In Renal Cell Carcinoma: A Meta-Analysis Of Available Clinical Trials
- (2019) Francesco Massari et al. Clinical Genitourinary Cancer
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Tivozanib for the treatment of renal cell carcinoma
- (2018) Matteo Santoni et al. EXPERT OPINION ON PHARMACOTHERAPY
- Results of phase I plus expansion cohorts of cabozantinib (Cabo) plus nivolumab (Nivo) and CaboNivo plus ipilimumab (Ipi) in patients (pts) with with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies.
- (2018) Rosa Maria Nadal et al. JOURNAL OF CLINICAL ONCOLOGY
- Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC).
- (2018) Bernard Escudier et al. JOURNAL OF CLINICAL ONCOLOGY
- IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
- (2018) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
- (2018) Michael B Atkins et al. LANCET ONCOLOGY
- Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
- (2018) Toni K Choueiri et al. LANCET ONCOLOGY
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
- (2018) Constantine S. Tam et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
- (2018) Jae Eun Cheong et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Targeting adenosine for cancer immunotherapy
- (2018) Robert D. Leone et al. Journal for ImmunoTherapy of Cancer
- Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present)
- (2018) Alessandro Leonetti et al. Future Oncology
- Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results.
- (2018) Chung-Han Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors
- (2018) Trevor R. Baybutt et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma
- (2018) Bimal Bhindi et al. EUROPEAN UROLOGY
- Liver X receptor activation reduces gastric cancer cell proliferation by suppressing Wnt signalling via LXRβ relocalization
- (2018) Qiang Wang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
- (2018) Johanna C. Bendell et al. ONCOLOGIST
- Altered cancer metabolism in mechanisms of immunotherapy resistance
- (2018) Rishab Ramapriyan et al. PHARMACOLOGY & THERAPEUTICS
- Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy
- (2018) Francesco Massari et al. Targeted Oncology
- Tim-3 and its role in regulating anti-tumor immunity
- (2017) Madhumita Das et al. IMMUNOLOGICAL REVIEWS
- LAG3 (CD223) as a cancer immunotherapy target
- (2017) Lawrence P. Andrews et al. IMMUNOLOGICAL REVIEWS
- Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Systemic Therapy for Metastatic Renal-Cell Carcinoma
- (2017) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liver X receptor as a drug target for the treatment of breast cancer
- (2016) Ying Wu et al. ANTI-CANCER DRUGS
- Rationale for anti-GITR cancer immunotherapy
- (2016) Deborah A. Knee et al. EUROPEAN JOURNAL OF CANCER
- Rationale for anti-OX40 cancer immunotherapy
- (2016) Sandrine Aspeslagh et al. EUROPEAN JOURNAL OF CANCER
- Selective histone deacetylase small molecule inhibitors: recent progress and perspectives
- (2016) Hai-Tao Qin et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy
- (2016) Alain Ravaud et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma
- (2015) Aurelie Guislain et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy
- (2015) L. Zhai et al. CLINICAL CANCER RESEARCH
- T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival
- (2015) Meng Yang et al. JOURNAL OF SURGICAL ONCOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Resistance to Antiangiogenic Therapy Is Associated with an Immunosuppressive Tumor Microenvironment in Metastatic Renal Cell Carcinoma
- (2015) X.-D. Liu et al. Cancer Immunology Research
- Prognostic Value of T Cell Immunoglobulin Mucin-3 in Prostate Cancer
- (2013) Yong-Rui Piao et al. Asian Pacific Journal of Cancer Prevention
- Tim-3 Expression in Cervical Cancer Promotes Tumor Metastasis
- (2013) Yang Cao et al. PLoS One
- Decreased Galectin-9 and Increased Tim-3 Expression Are Related to Poor Prognosis in Gastric Cancer
- (2013) Jing Jiang et al. PLoS One
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Aerobic Glycolysis: Meeting the Metabolic Requirements of Cell Proliferation
- (2011) Sophia Y. Lunt et al. Annual Review of Cell and Developmental Biology
- Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy
- (2011) Eric Tartour et al. CANCER AND METASTASIS REVIEWS
- Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans
- (2011) Caroline J. Breitbach et al. NATURE
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1
- (2010) Katrin Düvel et al. MOLECULAR CELL
- Effect of arginase II on L-arginine depletion and cell growth in murine cell lines of renal cell carcinoma
- (2008) David J Tate et al. Journal of Hematology & Oncology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started